Passage Bio (PASG) Competitors $7.00 +0.03 (+0.43%) Closing price 09/12/2025 03:55 PM EasternExtended Trading$6.78 -0.22 (-3.13%) As of 09/12/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PASG vs. CRDL, ATRA, STRO, XBIT, ARTV, VXRT, OVID, ABOS, QNCX, and KLRSShould you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Cardiol Therapeutics (CRDL), Atara Biotherapeutics (ATRA), Sutro Biopharma (STRO), XBiotech (XBIT), Artiva Biotherapeutics (ARTV), Vaxart (VXRT), Ovid Therapeutics (OVID), Acumen Pharmaceuticals (ABOS), Quince Therapeutics (QNCX), and Kalaris Therapeutics (KLRS). These companies are all part of the "pharmaceutical products" industry. Passage Bio vs. Its Competitors Cardiol Therapeutics Atara Biotherapeutics Sutro Biopharma XBiotech Artiva Biotherapeutics Vaxart Ovid Therapeutics Acumen Pharmaceuticals Quince Therapeutics Kalaris Therapeutics Cardiol Therapeutics (NASDAQ:CRDL) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation. Which has higher earnings and valuation, CRDL or PASG? Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiol TherapeuticsN/AN/A-$26.77M-$0.34-3.15Passage BioN/AN/A-$64.77M-$18.16-0.39 Which has more risk & volatility, CRDL or PASG? Cardiol Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Does the media favor CRDL or PASG? In the previous week, Cardiol Therapeutics had 1 more articles in the media than Passage Bio. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 2 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.95 beat Cardiol Therapeutics' score of 0.50 indicating that Passage Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CRDL or PASG? Cardiol Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 647.66%. Passage Bio has a consensus target price of $75.67, indicating a potential upside of 980.95%. Given Passage Bio's higher probable upside, analysts plainly believe Passage Bio is more favorable than Cardiol Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Passage Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CRDL or PASG more profitable? Passage Bio's return on equity of -103.87% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cardiol TherapeuticsN/A -232.26% -158.19% Passage Bio N/A -103.87%-59.95% Do institutionals and insiders believe in CRDL or PASG? 12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Passage Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryPassage Bio beats Cardiol Therapeutics on 8 of the 14 factors compared between the two stocks. Get Passage Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PASG vs. The Competition Export to ExcelMetricPassage BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.16M$3.20B$5.86B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-0.3921.4375.2025.97Price / SalesN/A430.69514.97181.13Price / CashN/A46.6837.5660.44Price / Book0.359.6112.156.29Net Income-$64.77M-$53.29M$3.29B$270.96M7 Day Performance-1.60%0.13%0.75%3.87%1 Month Performance9.72%5.61%4.82%4.88%1 Year Performance-56.61%10.49%60.59%26.12% Passage Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PASGPassage Bio3.9377 of 5 stars$7.00+0.4%$75.67+981.0%-53.1%$22.16MN/A-0.39130High Trading VolumeCRDLCardiol Therapeutics2.3295 of 5 stars$1.05-3.7%$8.00+661.9%-54.9%$91.25MN/A-3.0920Short Interest ↑ATRAAtara Biotherapeutics4.5426 of 5 stars$12.18-5.7%$21.00+72.4%+50.0%$90.67M$128.94M-28.32330Positive NewsSTROSutro Biopharma4.072 of 5 stars$0.98-7.3%$4.47+354.7%-80.3%$89.86M$62.04M-0.39240Analyst UpgradeGap DownXBITXBiotech1.9298 of 5 stars$2.74-6.2%N/A-59.7%$89.02M$4.01M-2.98100Positive NewsShort Interest ↓ARTVArtiva Biotherapeutics3.1337 of 5 stars$3.09-14.4%$17.00+450.2%-76.3%$88.18M$250K0.0081Positive NewsVXRTVaxart2.0631 of 5 stars$0.39+2.3%$2.00+419.5%-57.0%$88.14M$47.40M-1.43120Gap DownOVIDOvid Therapeutics4.5383 of 5 stars$1.24+0.8%$3.10+150.0%+13.5%$87.46M$570K-2.3460Positive NewsABOSAcumen Pharmaceuticals2.7585 of 5 stars$1.41-2.1%$7.00+396.5%-46.1%$87.23MN/A-0.6220Gap UpQNCXQuince Therapeutics3.7286 of 5 stars$1.57-2.5%$8.14+418.7%+117.7%$86.48MN/A-1.4460News CoverageKLRSKalaris Therapeutics1.874 of 5 stars$4.64+0.4%$3.00-35.3%N/A$86.40MN/A0.00110News CoverageGap Down Related Companies and Tools Related Companies CRDL Alternatives ATRA Alternatives STRO Alternatives XBIT Alternatives ARTV Alternatives VXRT Alternatives OVID Alternatives ABOS Alternatives QNCX Alternatives KLRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PASG) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
